National Institutes of Health, a Component of the US Dept. of Health & Human Services

Columbia University

University of Washington

Gilad Ofek

Baoshan Zhang

Ivelin Georgiev

Peter D Kwong

Yongping Yang

Gwo-Yu Chuang

Mark Connors

John R Mascola

Gary J Nabel

Barney S Graham

Tongqing Zhou

Michael Gordon Joyce

Masaru Kanekiyo

Zhi-yong Yang

Jeffrey C Boyington

Jason Scott McLellan

Guillaume Stewart-Jones

Marie Pancera

Man Chen

Mallika Sastry

Jason Gorman

Cinque Soto

Rebecca S Rudicell

Jiang Zhu

Jinghe Huang

Lei Chen

Leo Laub

Sanjay Srivatsan

Richard Schwartz

Young Do Kwon

Lawrence Shapiro

Lisa Kueltzo

Krisha McKee

Sijy O'Dell

Mark Louder

Mangaiarkarasi Asokan

Jonathan Cooper

Kevin Carlton

Michael Bender

Amarendra Pegu

Tatyana Gindin

John Mascola

Richard Wyatt

Xueling Wu

Yuxing Li

Robert Bailer

Min Tang

Jason S Mclellan

Ivelin Stefanov Georgiev

William R Schief

Leo B Laub

Gary Nabel

Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.

10E8 neutralizing antibody variants that bind to the MPER region of HIV-1 GP41 and their use

Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.

Prefusion RSV F proteins and their use

Neutralizing antibodies to HIV-1 GP41 and their use

Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.

Neutralizing GP41 antibodies and their use

This invention relates to novel peptide immunogens that generate an immune response in mammals against HIV gp41, to pharmaceutical compositions that comprise such immunogens, and to methods of treating Immunodeficiency disease, especially HIV infection and AIDS, that employ such pharmaceutical compositions.

Human immunodeficiency virus (HIV) immunization strategies employing conformationally-stabilized, surface-occluded peptides comprising a gp41 2F5 epitope in association with lipid

Growing community of inventors

Washington, DC, United States of America

Gilad Ofek